Assessment of tumor apoptotic indices using cleaved caspase 3 immunohistochemistry showed no difference between the PyV MT/jnk2+/+ and the PyV MT/jnk2−/− tumors (Figure 1C). This evidence concerns the gene MAPK9 and neoplasm.